

**MINUTES OF THE GENERAL MEETING AT THE 2014 SETAC NORTH AMERICA CONFERENCE (VANCOUVER)
HELD ON WEDNESDAY 12TH NOVEMBER 2014, 16:30 – 17:30**

PRESENT: 41

APOLOGIES: Mike Williams! Not really worth doing this except for PAG committee members

1 SUMMARY OF EXPERTS WORKSHOP ON ERA OF IONOGENIC COMPOUNDS

Mark Bonnell provided a brief summary on what occurred at the expert's workshop on ionogenic compounds – a workshop that immediately preceded the SETAC-NA conference. This workshop was born out of a shared interest from the SETAC pharmaceutical advisory group and the SETAC bioaccumulation advisory. The group specifically focused on ADME, fate/effects and ecotoxicity of ionogenic compounds. Four publications will result from this meeting.

<i>RESOLVED/NOTED</i>	Outcome e.g. Members in attendance accept the report through show of hands or one member accepts and seconded by another
-----------------------	--

2 SPECIAL ISSUE ON PHARMACEUTICALS IN ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY

If you are interested in submitting a manuscript, review article, or synthesis piece for this special issue please contact Mike (mike.williams@csiro.au) by the 14th November with a tentative title, proposed authors and abstract describing your contribution. The final date for submission of manuscripts will be 28th February 2015.

<i>NOTED</i>	Additionally: the American Association of Pharmaceutical Scientists (AAPS) Journal is seeking articles for a "rolling online" theme issue, Pharmaceuticals and Personal Care Products (PPCPs) in the Environment. The journal's audience is primarily pharm. scientists and those interested in green chemistry/pharma.
--------------	---

3 FUTURE CONFERENCES, WORKSHOPS AND MEETINGS

SESSS

Barcelona

Other meetings to PAG needs to promote/address

<i>NOTED</i>	<p>Three SETAC Barcelona sessions are especially relevant for the PAG.</p> <ol style="list-style-type: none"> 1) Special symposia on antimicrobials 2) Behavioral session – broad session but will include pharmaceuticals 3) General pharmaceutical sessions; especially looking for direct evidence of real consequences of real environmental exposures
--------------	---

4 OTHER BUSINESS

- Lively discussion on avenues for further research

NOTED

- Several people mentioned a need to better understand pharmaceutical exposure and if pharmaceuticals represented a global concern, or a regional/region-specific concern (based usage patterns, quality of WWTP, dilution, presence/absence of manufacturing facilities).
- Need for in-stream evidence that shows population level effects for PPCPs. (Analogous to the ELA work by Kidd et al).
- Is there a need for a PBT “reality check”? Do we really understand if these compounds are or are not PBT? (or pseudo PBT)?

ACTION LIST - TO DO

Document Number	Action Number	Follow Up Action Required	Implement. Date	Officer(s) Responsible	Outcome